Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186329 · ClinicalTrials.gov registry record · Phase 4
BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00186329: Completed Phase 4 study, sponsored by Stanford University.
NCT00186329 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186329, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Many patients with exacerbations of heart failure have significant concomitant kidney dysfunction. The combination of these two conditions makes pharmacological management difficult. In this study, we plan to randomize patients with heart failure and kidney dysfunction to receive infusions of Natrecor (B-type Natriuretic Peptide)--which may be beneficial to the management of these two diseases--or placebo.
Interventions
- DRUG Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186329
The ClinicalTrials.gov registry entry for NCT00186329 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo is the first listed.
NCT00186329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186329 about?
NCT00186329 is a clinical study titled "BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)". Many patients with exacerbations of heart failure have significant concomitant kidney dysfunction. The combination of these two conditions makes pharmacological management difficult. In this study, we plan to randomize patients with heart failure and kidney dysfunction to receive infusions of Natrec...
What is the current status of trial NCT00186329?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2004-03. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00186329?
The interventions under investigation include: Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo (DRUG).
Who is sponsoring clinical trial NCT00186329?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.